Pembrolizumab is a potent, highly selective, humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby activating T lymphocytes, which may affect both tumor cells and healthy cells (40). Here, PDCD1 is linked to neoplasm.